Table 1.

Effect of 10−7 M NE in perfused hearts on PSP, PDHA, and Mito [Ca2+]

Dietary Group
Ref n–6 PUFAn–3 PUFA
6 mo 24 mo 6 mo 24 mo6 mo 24 mo
PSP, mmHg
 Control 102.3 ± 2.398.2 ± 2.2 102.8 ± 2.5 97.3 ± 2.496.8 ± 2.2 98.8 ± 2.0
 NE227.5 ± 3.2* 218.0 ± 5.5* 230.3 ± 4.5* 220.7 ± 3.9* 218.0 ± 3.4* 215.0 ± 3.2*
Mito [Ca2+], nmol/mg protein
 Control0.33 ± 0.02 0.38 ± 0.03 0.43 ± 0.030.46 ± 0.04 0.24 ± 0.02 0.25 ± 0.05
 NE 0.88 ± 0.03* 1.34 ± 0.05*, 1.17 ± 0.05* 1.47 ± 0.01*, 0.80 ± 0.08*,1-153 0.96 ± 0.04*,,1-153
PDHA, %Total PDH
 Control 11.7 ± 0.6613.4 ± 1.56 13.6 ± 0.5220.5 ± 2.34 10.1 ± 0.5 16.0 ± 1.3
 NE 40.6 ± 2.24* 65.2 ± 17.5*, 57.7 ± 8.8*, 69.4 ± 11.1* 38.9 ± 1.28*,1-153 39.3 ± 6.1*,,1-153
  • Values are means ± SE; n = 6 in reference (Ref) and n–6 polyunsaturated fatty acid (PUFA) groups and 5 in n–3 PUFA group. Activation of pyruvate dehydrogenase (PDHA) is expressed as %total PDH, which was determined by additional perfusion with 5 mM dichloroacetate of subgroups of hearts for each age and diet. All PDH measures are normalized to citrate synthase content in each heart. Citrate synthase activity did not differ significantly among any of the groups, regardless of age or dietary lipid treatment. NE, norepinephrine; PSP, peak systolic pressure; Mito [Ca2+], mitochondrial Ca2+ concentration.

  • * P < 0.05 vs. control.

  • P < 0.05 vs. 6 mo.

  • P < 0.05 vs. Ref.

  • F1-153 P < 0.05 vs. n–6 PUFA.